In a report issued on August 1, Marc Goodman from SVB Securities maintained a Buy rating on AC Immune SA (ACIU – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $3.27, close to its 52-week low of $2.06. According to TipRanks.com, Goodman is a 1-star analyst with an average return of -0.4% and a 43.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $13.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-its-buy-rating-for-ac-immune-sa-aciu?utm_source=advfn.com&utm_medium=referral
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more AC Immune Charts.
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more AC Immune Charts.